Know Cancer

or
forgot password
  • cancer clinical trials in boston, MA

  • Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Massachusetts General Hospital
    Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma
    Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
    Brigham and Women's Hospital
    Boston, Massachusetts 02115
    Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
    Dana Farber Cancer Institute and Children's Hospital
    Boston, Massachusetts 02215-5450
    Acute Myeloid Leukemia
    Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Glioblastoma Multiforme
    Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Thyroid Cancer
    Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
    Dana Farber Cancer Institute

    Trial Locations
    Dana Farber Cancer Institute
    Brigham & Women's Hospital
    Refractory TdT-Positive Leukemia
    Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
    Massachusetts General Hospital

    Trial Locations
    Massachusetts General Hospital
    Dana Farber Cancer Institute
    Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
    D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
    Beth Israel Deaconess Medical Centre
    Boston, Massachusetts 02215
    Deep Vein Thrombosis, Pulmonary Embolism
    Study of Ramucirumab in Ovarian Cancer
    ImClone Investigational Site
    Boston, Massachusetts 02135
    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
    Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Hodgkin Lymphoma
    A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
    Dana Farber Cancer Institute
    Boston, Massachusetts 02115
    Myelofibrosis
    Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
    Dana Farber Cancer Institute (and Massachusetts General)
    Boston, Massachusetts 02115
    Multiple Myeloma
    BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
    1200.36.0002 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts
    Glioma
    A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Massachusetts General Hospital
    Dana Farber Cancer Institute
    Metastatic Castration-resistant Prostrate Cancer (mCRPC), Renal Cell Carcinoma (RCC), Metastatic Melanoma (MEL), Non-small Cell Lung Cancer (NSCLC)
    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
    Floating Hospital for Children at Tufts Medical Center
    Boston, Massachusetts 02111
    Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Essential Thrombocythemia, Extramedullary Plasmacytoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Juvenile Myelomonocytic Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Stage 0 Chronic Lymphocytic Leukemia, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
    A Phase II Study of AS1411 in Renal Cell Carcinoma
    Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Metastatic Renal Cell Carcinoma
    Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
    Dana Farber Cancer Institute Hematology / Oncology
    Boston, Massachusetts 02115
    Classical Hodgkin's Lymphoma (i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted)
    A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
    Site Reference ID/Investigator# 63588

    Trial Locations
    Site Reference ID/Investigator# 63588
    Site Reference ID/Investigator# 63591
    Hematologic Cancer
    Airway Epithelium Gene Expression: AEGIS II
    St. Elizabeth's Medical Center
    Boston, Massachusetts 02135-2997
    Lung Cancer
    Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114
    Ovarian Stromal Cancer
    Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Renal Cell Carcinoma
    Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
    Massachusetts Eye & Ear Infirmary
    Boston, Massachusetts 02114
    Choroidal Melanoma
    A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Malignant Glioma
    Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
    Beth-Israel Deaconess Medical Center
    Boston, Massachusetts
    Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
    Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114
    Melanoma
    Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Lung Cancer, Non Small Cell Lung Cancer
    Neuropsychological and Behavioral Testing in Young Patients With Cancer
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Floating Hospital for Children at Tufts Medical Center
    Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
    Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Beth-Israel Deaconess Medical Center
    Prostate Cancer
    Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
    Dana Farber Cancer Institute Hematology / Oncology
    Boston, Massachusetts 02115
    Leukemia
    Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Renal Cell Carcinoma, Kidney Cancer
    Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Massachusetts General Hospital Cancer Center
    Dana-Farber Cancer Institute
    Boston Medical Center
    Brigham and Women's Hospital
    Tufts Medical Center
    Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    Mucosal Melanoma, Acral Melanoma, Melanoma